Imprime PGG: Phase II started

Biothera said the Dana-Farber Cancer Institute began an open-label, U.S. Phase II trial to evaluate 4 mg/kg IV Imprime PGG plus IV Rituxan rituximab once weekly for 4 weeks in about 25 patients. ...